Teresa K Chen1,2, Aditya L Surapaneni2,3, Dan E Arking4, Christie M Ballantyne5, Eric Boerwinkle6,7, Jingsha Chen3, Josef Coresh8,2,3, Anna Köttgen3,9, Katalin Susztak10, Adrienne Tin11, Bing Yu6, Morgan E Grams3,12. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland tchen39@jhmi.edu. 2. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. McKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Medicine, Baylor College of Medicine, Houston, Texas. 6. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. 7. Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas. 8. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. Department of Data Driven Medicine, Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany. 10. Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 11. Department of Medicine, The University of Mississippi Medical Center, Jackson, Mississippi. 12. Department of Medicine, New York University Langone School of Medicine, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: The APOL1 risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How APOL1 risk variants relate to the circulating proteome warrants further investigation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m2), we evaluated associations of APOL1 risk variants with 6790 serum proteins (measured via SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1-5. Associated proteins were then evaluated as mediators of APOL1-associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m2). RESULTS: In the AASK study, having two (versus zero or one) APOL1 risk alleles was associated with lower serum levels of APOL1 (P=3.11E-13; P=3.12E-06 [two aptamers]), APOL2 (P=1.45E-10), CLSTN2 (P=2.66E-06), MMP-2 (P=2.96E-06), SPOCK2 (P=2.57E-05), and TIMP-2 (P=2.98E-05) proteins. In the ARIC study, APOL1 risk alleles were associated with APOL1 (P=1.28E-11); MMP-2 (P=0.004) and TIMP-2 (P=0.007) were associated only in an additive model, and APOL2 was not available. APOL1 high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort. CONCLUSIONS: APOL1 risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the APOL1-associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.
BACKGROUND AND OBJECTIVES: The APOL1 risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How APOL1 risk variants relate to the circulating proteome warrants further investigation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m2), we evaluated associations of APOL1 risk variants with 6790 serum proteins (measured via SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1-5. Associated proteins were then evaluated as mediators of APOL1-associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m2). RESULTS: In the AASK study, having two (versus zero or one) APOL1 risk alleles was associated with lower serum levels of APOL1 (P=3.11E-13; P=3.12E-06 [two aptamers]), APOL2 (P=1.45E-10), CLSTN2 (P=2.66E-06), MMP-2 (P=2.96E-06), SPOCK2 (P=2.57E-05), and TIMP-2 (P=2.98E-05) proteins. In the ARIC study, APOL1 risk alleles were associated with APOL1 (P=1.28E-11); MMP-2 (P=0.004) and TIMP-2 (P=0.007) were associated only in an additive model, and APOL2 was not available. APOL1 high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort. CONCLUSIONS: APOL1 risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the APOL1-associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.
Keywords:
AASK (African American Study of Kidney Disease and Hypertension); apolipoprotein L1; chronic kidney disease; end stage kidney disease; epidemiology and outcomes; genetic renal disease; proteomics; renal function decline
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak Journal: Nat Med Date: 2017-02-20 Impact factor: 53.440
Authors: Morgan E Grams; Casey M Rebholz; Yuan Chen; Andreea M Rawlings; Michelle M Estrella; Elizabeth Selvin; Lawrence J Appel; Adrienne Tin; Josef Coresh Journal: J Am Soc Nephrol Date: 2016-03-10 Impact factor: 10.121
Authors: B T Lee; V Kumar; T A Williams; R Abdi; A Bernhardy; C Dyer; S Conte; G Genovese; M D Ross; D J Friedman; R Gaston; E Milford; M R Pollak; A Chandraker Journal: Am J Transplant Date: 2012-04-04 Impact factor: 8.086
Authors: Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: G Hintsch; A Zurlinden; V Meskenaite; M Steuble; K Fink-Widmer; J Kinter; P Sonderegger Journal: Mol Cell Neurosci Date: 2002-11 Impact factor: 4.314
Authors: Allison Weckerle; James A Snipes; Dongmei Cheng; Abraham K Gebre; Julie A Reisz; Mariana Murea; Gregory S Shelness; Gregory A Hawkins; Cristina M Furdui; Barry I Freedman; John S Parks; Lijun Ma Journal: J Lipid Res Date: 2015-11-18 Impact factor: 5.922
Authors: Stephen A Williams; Peter Ganz; Nicholas J Wareham; Mika Kivimaki; Claudia Langenberg; Aroon D Hingorani; J P Casas; Claude Bouchard; Christian Jonasson; Mark A Sarzynski; Martin J Shipley; Leigh Alexander; Jessica Ash; Tim Bauer; Jessica Chadwick; Gargi Datta; Robert Kirk DeLisle; Yolanda Hagar; Michael Hinterberg; Rachel Ostroff; Sophie Weiss Journal: Nat Med Date: 2019-12-02 Impact factor: 53.440